[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

Roche's CT-996, an oral GLP-1 receptor agonist, demonstrated significant weight loss (-6.1%) within four weeks in obese participants without type 2 diabetes. CT-996 was well-tolerated, with gastrointestinal adverse events consistent with other GLP-1 agonists. Pharmacokinetic data supports a once-daily oral dosing regimen, potentially offering flexibility in meal timing. CT-996 is anticipated for use in achieving glycaemic control, inducing weight loss, and potentially for oral weight maintenance. Obesity remains a prevalent and undertreated health concern globally, with incretin modalities playing a crucial role in addressing unmet needs. CT-996, along with Roche's other incretin-based assets, aims to provide a comprehensive portfolio of treatments for obesity and related metabolic conditions. GLP-1 agonists have shown clinical efficacy as targets in obesity, with potential benefits beyond glucose modulation. Roche's commitment to sustainability has been recognized for 15 consecutive years by the Dow Jones Sustainability Indices. CT-996 is currently in Phase I clinical development, with Phase II expected to follow based on positive Phase I results. Roche's broad metabolism portfolio includes both oral and injectable incretin modalities, addressing the spectrum of related diseases and unmet needs in obesity management.